Related Experiment Videos
The current management of pancreatic neuroendocrine tumors
Trevor A Ellison1, Barish H Edil
1Department of Surgery, The Johns Hopkins Hospital, 1550 Orleans Street, CRB II, Room 506, Baltimore, MD 21287, USA.
Abstract:
PanNETs constitute a rare and heterogeneous group of pancreatic neoplasms whose overall prognosis is better than the more common pancreatic adenocarcinoma. Although surgery is the only treatment that provides a cure, many adjuvant therapies have been explored with some new, exciting, targeted therapies just approved for PanNETs. With growing interest in this type of neoplasm, an increasing number of clinical trials and natural history studies should shed light on the best management for these patients.
Insights
Pancreatic neuroendocrine tumors (PanNETs) are rare but have a better prognosis than pancreatic cancer. Research is exploring new targeted therapies and clinical trials to improve PanNET patient management.
Area of Science:
- Oncology
- Gastroenterology
- Endocrinology
Background:
- Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms.
- PanNETs exhibit heterogeneity and a generally better prognosis than pancreatic adenocarcinoma.
- Surgery remains the only curative treatment for PanNETs.
Purpose of the Study:
- To review the current understanding and management of PanNETs.
- To highlight advancements in adjuvant and targeted therapies for PanNETs.
- To emphasize the growing interest and ongoing research in PanNETs.
Main Methods:
- Literature review of existing studies on PanNETs.
- Analysis of current treatment strategies, including surgery and adjuvant therapies.
- Overview of recently approved targeted therapies and ongoing clinical trials.
Main Results:
- PanNETs represent a distinct group of pancreatic tumors with unique characteristics.
- Adjuvant therapies, including novel targeted treatments, are increasingly explored for PanNETs.
- Significant interest is driving new clinical trials and natural history studies.
Conclusions:
- Despite rarity, PanNETs warrant dedicated research due to their distinct clinical behavior.
- Advancements in targeted therapies offer new hope for PanNET management.
- Further research, including clinical trials, is crucial for optimizing patient outcomes.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management